StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(-94.0%)
USD 0.0
(-94.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2022 | 95.62 Thousand USD | -76.61% |
| 2021 | 408.8 Thousand USD | 15.16% |
| 2020 | 354.99 Thousand USD | 304.6% |
| 2019 | 87.73 Thousand USD | -20.93% |
| 2018 | 110.95 Thousand USD | 29.54% |
| 2017 | 85.65 Thousand USD | -13.31% |
| 2016 | 98.81 Thousand USD | 0.0% |
| 2015 | - USD | 100.0% |
| 2014 | -90.82 Thousand USD | 33.11% |
| 2013 | -135.76 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 230.89 Thousand USD | 37.85% |
| 2003 | 167.49 Thousand USD | 283.14% |
| 2002 | 43.71 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 100.0% |
| 1999 | -193.65 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 22.57 Thousand USD | 0.11% |
| 2024 Q1 | 22.54 Thousand USD | 0.0% |
| 2023 Q1 | 82.94 Thousand USD | -13.26% |
| 2023 Q2 | 82.94 Thousand USD | 0.0% |
| 2023 Q3 | 22.57 Thousand USD | -72.79% |
| 2022 Q2 | 241.69 Thousand USD | -29.76% |
| 2022 Q1 | 344.09 Thousand USD | -15.83% |
| 2022 FY | 95.62 Thousand USD | -76.61% |
| 2022 Q4 | 95.62 Thousand USD | -59.89% |
| 2022 Q3 | 238.39 Thousand USD | -1.37% |
| 2021 FY | 408.8 Thousand USD | 15.16% |
| 2021 Q4 | 408.8 Thousand USD | -43.33% |
| 2021 Q3 | 721.32 Thousand USD | 35.5% |
| 2021 Q2 | 532.33 Thousand USD | 23.64% |
| 2021 Q1 | 430.55 Thousand USD | 21.28% |
| 2020 Q4 | 354.99 Thousand USD | -42.8% |
| 2020 FY | 354.99 Thousand USD | 304.6% |
| 2020 Q1 | 121.72 Thousand USD | 38.74% |
| 2020 Q2 | 220.21 Thousand USD | 80.91% |
| 2020 Q3 | 620.62 Thousand USD | 181.82% |
| 2019 Q4 | 87.73 Thousand USD | -59.63% |
| 2019 Q2 | 215.3 Thousand USD | 59.23% |
| 2019 Q1 | 135.22 Thousand USD | 21.87% |
| 2019 Q3 | 217.32 Thousand USD | 0.94% |
| 2019 FY | 87.73 Thousand USD | -20.93% |
| 2018 Q4 | 110.95 Thousand USD | -21.53% |
| 2018 FY | 110.95 Thousand USD | 29.54% |
| 2018 Q1 | 76.03 Thousand USD | -11.24% |
| 2018 Q2 | 131.36 Thousand USD | 72.78% |
| 2018 Q3 | 141.4 Thousand USD | 7.64% |
| 2017 Q4 | 85.65 Thousand USD | 0.28% |
| 2017 Q3 | 85.41 Thousand USD | -14.78% |
| 2017 FY | 85.65 Thousand USD | -13.31% |
| 2017 Q1 | 117.12 Thousand USD | 18.53% |
| 2017 Q2 | 100.23 Thousand USD | -14.42% |
| 2016 Q1 | 185.91 Thousand USD | 893.88% |
| 2016 FY | 98.81 Thousand USD | 0.0% |
| 2016 Q4 | 98.81 Thousand USD | -19.94% |
| 2016 Q3 | 123.42 Thousand USD | -2.15% |
| 2016 Q2 | 126.13 Thousand USD | -32.15% |
| 2015 FY | - USD | 100.0% |
| 2015 Q4 | -23.41 Thousand USD | 23.25% |
| 2015 Q1 | -59.46 Thousand USD | 34.52% |
| 2015 Q2 | -32.49 Thousand USD | 45.35% |
| 2015 Q3 | -30.51 Thousand USD | 6.11% |
| 2014 Q2 | 1.00 USD | -50.0% |
| 2014 FY | - USD | 33.11% |
| 2014 Q1 | 2.00 USD | 100.0% |
| 2014 Q4 | -90.82 Thousand USD | -38.41% |
| 2014 Q3 | -65.61 Thousand USD | -6561812.46% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | 63.76 Thousand USD | 77483696.7% |
| 2013 Q1 | 2.00 USD | 0.0% |
| 2013 Q2 | -0.08 USD | -104.11% |
| 2013 Q4 | -135.76 Thousand USD | -312.9% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q2 | 267.35 Thousand USD | 106.62% |
| 2005 Q3 | 437.54 Thousand USD | 63.66% |
| 2005 Q4 | - USD | -100.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q1 | 129.39 Thousand USD | -43.96% |
| 2004 Q1 | 258.79 Thousand USD | 54.51% |
| 2004 Q3 | 106.52 Thousand USD | -35.79% |
| 2004 Q4 | 230.89 Thousand USD | 116.74% |
| 2004 FY | 230.89 Thousand USD | 37.85% |
| 2004 Q2 | 165.9 Thousand USD | -35.89% |
| 2003 FY | 167.49 Thousand USD | 283.14% |
| 2003 Q4 | 167.49 Thousand USD | 0.0% |
| 2003 Q3 | - USD | -100.0% |
| 2003 Q2 | 169.89 Thousand USD | 475.04% |
| 2003 Q1 | 29.54 Thousand USD | -30.89% |
| 2002 Q1 | 31.32 Thousand USD | -75.47% |
| 2002 Q3 | 58.61 Thousand USD | 0.0% |
| 2002 Q4 | 42.74 Thousand USD | -27.07% |
| 2002 FY | 43.71 Thousand USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q4 | 127.74 Thousand USD | 0.0% |
| 2001 Q1 | 1.00 USD | 214748364900.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | 2.00 USD | 100.0% |
| 2000 Q3 | 1.00 USD | 0.0% |
| 2000 FY | - USD | 100.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | -100.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| American Bio Medica Corporation | 379 Thousand USD | 74.77% |
| Arrayit Corporation | 464.19 Thousand USD | 79.401% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 757 Thousand USD | 87.368% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | -2385.00 USD | 4109.266% |
| DermTech, Inc. | 1 Million USD | 90.476% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.29 Million USD | 97.102% |
| HTG Molecular Diagnostics, Inc. | 909.32 Thousand USD | 89.484% |
| iMD Companies, Inc. | 38.31 Thousand USD | -149.559% |
| IDenta Corp. | 442.28 Thousand USD | 78.38% |
| Interpace Biosciences, Inc. | 1.22 Million USD | 92.207% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 163.13 Thousand USD | 41.385% |
| Lumos Diagnostics Holdings Limited | 784 Thousand USD | 87.803% |
| Many Bright Ideas Technologies Inc. | -375.00 USD | 25598.933% |
| Medical Imaging Corp. | - USD | -Infinity% |
| NovelStem International Corp. | - USD | -Infinity% |
| Optigenex Inc. | 468.77 Thousand USD | 79.602% |
| PharmChem, Inc. | 391.93 Thousand USD | 75.603% |
| Proteome Sciences plc | 1.06 Million USD | 91.026% |
| Response Genetics, Inc | 133 Thousand USD | 28.105% |
| Rennova Health, Inc. | 242.64 Thousand USD | 60.592% |
| RushNet, Inc. | - USD | -Infinity% |
| ScreenPro Security Inc. | 73.89 Thousand USD | -29.398% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| Todos Medical Ltd. | 1.02 Million USD | 90.635% |